 ras Proteins
"ras Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small, monomeric GTP-binding proteins encoded by ras genes (GENES, RAS). The protooncogene-derived protein, PROTO-ONCOGENE PROTEIN P21(RAS), plays a role in normal cellular growth, differentiation and development. The oncogene-derived protein (ONCOGENE PROTEIN P21(RAS)) can play a role in aberrant cellular regulation during neoplastic cell transformation (CELL TRANSFORMATION, NEOPLASTIC). This enzyme was formerly listed as EC 3.6.1.47.
| Descriptor ID |
D018631
|
| MeSH Number(s) |
D08.811.277.040.330.300.400.500 D12.644.360.525.500 D12.776.157.325.515.500 D12.776.476.525.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "ras Proteins".
Below are MeSH descriptors whose meaning is more specific than "ras Proteins".
This graph shows the total number of publications written about "ras Proteins" by people in UAMS Profiles by year, and whether "ras Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2015 | 1 | 3 | 4 | | 2014 | 1 | 2 | 3 | | 2013 | 6 | 0 | 6 | | 2012 | 1 | 3 | 4 | | 2011 | 3 | 0 | 3 | | 2010 | 3 | 0 | 3 | | 2009 | 1 | 1 | 2 | | 2008 | 2 | 0 | 2 | | 2007 | 0 | 1 | 1 | | 2005 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1998 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1994 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "ras Proteins" by people in Profiles over the past ten years.
-
Fowlkes JL, Thrailkill KM, Bunn RC. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis. Bone. 2021 11; 152:116060.
-
Deshpande S, Tytarenko RG, Wang Y, Boyle EM, Ashby C, Schinke CD, Thanendrarajan S, Zangari M, Zhan F, Davies FE, Morgan GJ, van Rhee F, Walker BA. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. Eur J Haematol. 2021 Feb; 106(2):230-240.
-
Hiatt SM, Neu MB, Ramaker RC, Hardigan AA, Prokop JW, Hancarova M, Prchalova D, Havlovicova M, Prchal J, Stranecky V, Yim DKC, Powis Z, Keren B, Nava C, Mignot C, Rio M, Revah-Politi A, Hemati P, Stong N, Iglesias AD, Suchy SF, Willaert R, Wentzensen IM, Wheeler PG, Brick L, Kozenko M, Hurst ACE, Wheless JW, Lacassie Y, Myers RM, Barsh GS, Sedlacek Z, Cooper GM. De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small GTPase, cause intellectual disability and developmental delay. PLoS Genet. 2018 11; 14(11):e1007671.
-
Liu YL, Yan Y, Webster C, Shao L, Lensing SY, Ni H, Feng W, Colorado N, Pathak R, Xiang Z, Hauer-Jensen M, Li S, Zhou D, Emanuel PD. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood. 2016 Apr 14; 127(15):1912-22.
-
Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 01; 6(38):41275-89.
-
Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015 Dec 11; 350(6266):1387-90.
-
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015 Nov 20; 33(33):3911-20.
-
Meyer K, Kwon YC, Liu S, Hagedorn CH, Ray RB, Ray R. Interferon-a inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Sci Rep. 2015 Mar 11; 5:9012.
-
Bauer MA, Chavan SS, Peterson EA, Heuck CJ, Johann DJ. Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing. BMC Bioinformatics. 2014; 15 Suppl 11:S3.
-
Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ. Biology and treatment of myeloma. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S65-70.
-
Malhotra N, Jackson SA, Freed LL, Styn MA, Sidawy MK, Haddad NG, Finkelstein SD. The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. BMC Gastroenterol. 2014 Aug 01; 14:135.
-
Pai RK, Hartman DJ, Gonzalo DH, Lai KK, Downs-Kelly E, Goldblum JR, Liu X, Patil DT, Bennett AE, Plesec TP, Kuan SF, Nikiforova MN, Shadrach B, Pai RK. Serrated lesions of the appendix frequently harbor KRAS mutations and not BRAF mutations indicating a distinctly different serrated neoplastic pathway in the appendix. Hum Pathol. 2014 Feb; 45(2):227-35.
-
Levinsohn JL, Teng J, Craiglow BG, Loring EC, Burrow TA, Mane SS, Overton JD, Lifton RP, McNiff JM, Lucky AW, Choate KA. Somatic HRAS p.G12S mutation causes woolly hair and epidermal nevi. J Invest Dermatol. 2014 Apr; 134(4):1149-1152.
-
Deftereos G, Finkelstein SD, Jackson SA, Ellsworth EM, Krishnamurti U, Liu Y, Silverman JF, Binkert CR, Ujevich BA, Mohanty A. The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions. Mod Pathol. 2014 Apr; 27(4):594-601.
-
Frett B, Wang Y, Li HY. Targeting the K-Ras/PDEd protein-protein interaction: the solution for Ras-driven cancers or just another therapeutic mirage? ChemMedChem. 2013 Oct; 8(10):1620-2.
-
Wang Y, Kaiser CE, Frett B, Li HY. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem. 2013 Jul 11; 56(13):5219-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|